Correction to: Scientific Reports https://doi.org/10.1038/s41598-018-23848-8, published online 04 April 2018
This Article contains errors in the Results section.
“The median stage-adjusted survival time was 7.9 months longer in patients with the highest levels of TRAIL compared to those with the lowest levels (Table 2).”
should read:
“The median stage-adjusted survival time was 7.1 months longer in patients with the highest levels of TRAIL compared to those with the lowest levels (Table 2).”
In addition, this Article contains errors in Table 1, where the reported numbers of patients under the ‘Regular Aspirin use’ subheading are incorrect. The correct totals for ‘No’ are 32 (100.0) and 97 (96.0) under Early-stage and Late-Stage respectively, and for ‘Yes’ the correct totals are 0 (0.0) and 4(4.0) respectively.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Liu, Z., Kemp, T.J., Gao, YT. et al. Author Correction: Circulating Levels of Inflammatory Proteins and Survival in Patients with Gallbladder Cancer. Sci Rep 10, 2680 (2020). https://doi.org/10.1038/s41598-020-59761-2
Published:
DOI: https://doi.org/10.1038/s41598-020-59761-2
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
